Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Sarcoma 2Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Cholangiocarcinoma 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Sarcoma × surufatinib × Clear all
NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡